Contribute Try STAT+ Today

Hello, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? Perhaps a cup or two of stimulation is in order. As you know, a prescription is not required. So feel free to indulge as you attack the laundry list of online meetings and deadlines that await. Meanwhile, we have once again assembled a list of tidbits for you to peruse and help you on your way. Hope you have a smashing day, and, as always, do drop us a line when you hear something interesting. …

An experimental Pfizer (PFE) oral drug to treat Covid-19 at the first sign of illness could be available by the end of the year, CNBC tells us. The company last month began an early-stage clinical trial testing a new antiviral therapy for the disease. The drug is a protease inhibitor, which works by inhibiting an enzyme that the virus needs to replicate in human cells. Protease inhibitors are used to treat HIV and hepatitis C. If trials go well and the Food and Drug Administration approves it, the drug could be distributed across the U.S. by the end of the year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Good luck to Pfizer in getting their protease inhibitor tested and shown safe and effective for Covid19. Merck, who has been testing their antiviral Molnupiravir in a randomized clinical trial in the US when there were 50,000 new cases a day, still took 8 months to recruit 1,400 participants. How is Pfizer going to find the patients when the number of new patients decreases to 2,000 a day and eventually down to 200 new cases a day?

Comments are closed.